Free Trial
→ Elon's next millionaires start October 24? (From Behind the Markets) (Ad)tc pixel Free KRMD Stock Alerts

KORU Medical Systems (KRMD) Financials

KORU Medical Systems logo
$3.02 +0.02 (+0.50%)
As of 02:06 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for KORU Medical Systems

Annual Income Statements for KORU Medical Systems

This table shows KORU Medical Systems' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 2/29/2016 2/29/2016 2/28/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 0.78 0.78 -0.53 0.56 -1.18 -4.56 -8.66 -14 -6.07 -2.64
Consolidated Net Income / (Loss)		 0.78 0.78 -0.53 0.56 -1.21 -4.56 -8.66 -14 -6.07 -2.64
Net Income / (Loss) Continuing Operations		 0.78 0.78 -0.53 0.56 -1.18 -4.56 -8.66 -14 -6.07 -2.64
Total Pre-Tax Income 		1.14 1.14 -0.78 0.70 1.19 -6.36 -11 -9.77 -6.06 -2.62
Total Operating Income		 1.18 1.18 -0.74 0.59 -1.25 -7.03 -11 -10 -6.45 -2.97
Total Gross Profit		 7.60 7.60 7.57 15 15 14 15 17 21 26
Total Revenue		 12 12 12 23 24 23 28 29 34 41
Operating Revenue		 12 12 12 23 24 23 28 29 34 41
Total Cost of Revenue		 4.64 4.64 4.72 8.31 9.24 9.72 13 12 12 16
Operating Cost of Revenue		 4.64 4.64 4.72 8.31 9.24 9.72 13 12 12 16
Total Operating Expenses		 6.42 6.42 8.31 14 16 21 26 27 28 29
Selling, General & Admin Expense		 5.94 5.94 7.77 9.77 12 18 21 20 22 23
Research & Development Expense		 0.21 0.21 0.24 0.74 1.30 2.47 4.96 5.74 5.26 4.39
Depreciation Expense		 0.27 0.27 0.30 0.34 0.42 0.46 0.59 0.87 0.89 0.81
Total Other Income / (Expense), net		 -0.04 -0.04 -0.04 0.11 0.06 -0.02 0.11 0.50 0.38 0.36
Interest & Investment Income		 - - - - - - - - 0.44 0.29
Other Income / (Expense), net		 -0.04 -0.04 -0.04 0.11 0.06 -0.02 0.11 0.50 -0.06 0.06
Income Tax Expense		 0.36 0.36 -0.24 0.13 -0.02 -1.80 -2.01 3.97 0.00 0.02
Basic Earnings per Share		 $0.02 $0.02 ($0.01) $0.01 ($0.03) ($0.10) ($0.19) ($0.30) ($0.13) ($0.06)
Weighted Average Basic Shares Outstanding		 37.99M 37.99M 37.83M 38.78M 41.93M 44.39M 45.00M 45.60M 45.80M 46.19M
Diluted Earnings per Share		 $0.02 $0.02 ($0.01) $0.01 ($0.03) ($0.10) ($0.19) ($0.30) ($0.13) ($0.06)
Weighted Average Diluted Shares Outstanding		 37.99M 37.99M 37.88M 39.06M 41.93M 44.39M 45.00M 45.60M 45.80M 46.19M
Weighted Average Basic & Diluted Shares Outstanding		 37.97M - 37.82M - 44.48M 44.67M 45.52M 45.71M 45.96M 46.37M

Quarterly Income Statements for KORU Medical Systems

This table shows KORU Medical Systems' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -7.47 -1.94 -0.99 -1.58 -1.56 -1.17 -0.21 -0.78 -0.49 -0.81 0.25
Consolidated Net Income / (Loss)		 -7.47 -1.94 -0.99 -1.58 -1.56 -1.17 -0.21 -0.78 -0.49 -0.81 0.25
Net Income / (Loss) Continuing Operations		 -7.47 -1.94 -0.99 -1.58 -1.56 -1.17 -0.21 -0.78 -0.49 -0.81 0.25
Total Pre-Tax Income 		-2.02 -1.94 -0.99 -1.58 -1.56 -1.17 -0.19 -0.78 -0.48 -0.81 0.26
Total Operating Income		 -2.20 -1.96 -1.19 -1.70 -1.59 -1.25 -0.31 -0.87 -0.55 -0.86 0.63
Total Gross Profit		 4.33 5.10 5.48 5.19 5.56 6.05 6.48 6.26 6.82 7.23 7.85
Total Revenue		 7.19 8.20 8.43 8.18 8.84 9.64 10 10 11 12 12
Operating Revenue		 7.19 8.20 8.43 8.18 8.84 9.64 10 10 11 12 12
Total Cost of Revenue		 2.85 3.09 2.95 2.99 3.28 3.59 3.72 4.14 4.08 4.53 4.20
Operating Cost of Revenue		 2.85 3.09 2.95 2.99 3.28 3.59 3.72 4.14 4.08 4.53 4.20
Total Operating Expenses		 6.53 7.06 6.67 6.89 7.15 7.29 6.79 7.13 7.36 8.10 7.22
Selling, General & Admin Expense		 5.01 5.36 5.32 5.13 5.83 5.96 5.38 5.99 6.04 6.58 5.94
Research & Development Expense		 1.29 1.48 1.13 1.53 1.11 1.11 1.19 0.93 1.14 1.32 1.07
Depreciation Expense		 0.23 0.23 0.22 0.23 0.21 0.22 0.21 0.20 0.18 0.20 0.21
Total Other Income / (Expense), net		 0.18 0.03 0.20 0.12 0.03 0.08 0.12 0.09 0.06 0.06 -0.37
Interest & Investment Income		 - - - 0.11 - 0.07 0.08 0.07 - 0.08 0.06
Other Income / (Expense), net		 0.18 0.03 0.20 0.01 0.03 0.01 0.04 0.01 -0.15 -0.02 -0.43
Income Tax Expense		 5.45 0.00 0.00 0.00 0.00 0.00 0.02 -0.00 0.00 0.00 0.01
Basic Earnings per Share		 ($0.17) $0.04 - - ($0.04) ($0.03) $0.00 - - ($0.02) $0.01
Weighted Average Basic Shares Outstanding		 45.60M 45.71M 45.86M 45.84M 45.80M 45.98M 46.19M 46.32M 46.19M 46.36M 46.08M
Diluted Earnings per Share		 ($0.17) $0.04 $0.02 $0.03 ($0.04) ($0.03) $0.00 $0.02 ($0.11) ($0.02) $0.01
Weighted Average Diluted Shares Outstanding		 45.60M 45.71M 45.81M 45.85M 45.80M 45.98M 46.19M 46.24M 46.19M 46.36M 49.51M
Weighted Average Basic & Diluted Shares Outstanding		 45.71M 45.76M 45.86M 45.84M 45.96M 46.14M 46.23M 46.32M 46.37M 45.93M 46.17M

Annual Cash Flow Statements for KORU Medical Systems

This table details how cash moves in and out of KORU Medical Systems' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 2/28/2015 2/29/2016 2/28/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.33 1.64 -0.89 2.13 21 -1.98 -7.93 -5.93 -1.90 -0.71
Net Cash From Operating Activities		 0.83 1.91 -0.33 0.32 -0.74 -4.32 -5.40 -4.89 -0.32 0.46
Net Cash From Continuing Operating Activities		 0.83 1.91 -0.33 0.32 -0.74 -4.32 -5.40 -4.89 -0.32 0.46
Net Income / (Loss) Continuing Operations		 0.75 0.78 -0.53 0.56 -1.21 -4.56 -8.66 -14 -6.07 -2.64
Consolidated Net Income / (Loss)		 0.75 0.78 -0.53 0.56 -1.21 -4.56 -8.66 -14 -6.07 -2.64
Depreciation Expense		 0.28 0.27 0.30 0.34 0.42 0.46 0.59 0.87 0.89 0.81
Non-Cash Adjustments To Reconcile Net Income		 -0.01 0.09 0.16 1.15 2.88 2.71 3.29 2.81 2.88 2.61
Changes in Operating Assets and Liabilities, net		 -0.28 0.74 -0.29 -1.73 -2.87 -2.93 -0.62 5.17 1.97 -0.32
Net Cash From Investing Activities		 -0.74 -0.19 -0.42 1.31 -1.04 -0.37 -2.80 -0.81 -1.33 -0.95
Net Cash From Continuing Investing Activities		 -0.74 -0.19 -0.42 1.31 -1.04 -0.37 -2.80 -0.81 -1.33 -0.95
Purchase of Property, Plant & Equipment		 -0.59 -0.12 -0.20 -0.20 -0.92 -0.35 -2.76 -0.78 -1.30 -0.93
Acquisitions		 -0.15 -0.08 -0.21 -0.22 -0.14 -0.03 -0.04 -0.03 -0.04 -0.02
Sale of Property, Plant & Equipment		 0.00 0.01 - 0.22 0.03 0.01 - 0.00 0.01 0.01
Net Cash From Financing Activities		 0.25 -0.08 -0.14 0.50 23 2.71 0.28 -0.22 -0.25 -0.22
Net Cash From Continuing Financing Activities		 0.25 -0.08 -0.14 0.50 23 2.71 0.28 -0.22 -0.25 -0.22
Repayment of Debt		 - - - 0.00 - 0.51 -0.08 0.57 - 0.41
Other Financing Activities, net		 - 0.00 -0.04 -0.00 -0.01 -0.00 -0.05 -0.78 -0.74 -0.63
Cash Interest Paid		 0.00 0.00 0.00 0.00 0.03 0.01 0.03 0.05 0.07 0.06
Cash Income Taxes Paid		 0.49 0.26 0.19 0.13 0.32 0.00 0.00 0.00 0.00 0.01

Quarterly Cash Flow Statements for KORU Medical Systems

This table details how cash moves in and out of KORU Medical Systems' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 0.71 -0.66 -0.36 -1.65 0.77 -0.85 -0.68 0.41 0.41 -0.10 -0.48
Net Cash From Operating Activities		 1.10 -0.35 0.01 -0.92 0.94 -0.24 -0.46 0.07 1.09 0.01 0.22
Net Cash From Continuing Operating Activities		 1.10 -0.35 0.01 -0.92 0.94 -0.24 -0.46 0.07 1.09 0.01 0.22
Net Income / (Loss) Continuing Operations		 -7.47 -1.94 -0.99 -1.58 -1.56 -1.17 -0.21 -0.78 -0.49 -0.81 0.25
Consolidated Net Income / (Loss)		 -7.47 -1.94 -0.99 -1.58 -1.56 -1.17 -0.21 -0.78 -0.49 -0.81 0.25
Depreciation Expense		 0.23 0.23 0.22 0.23 0.21 0.22 0.21 0.20 0.18 0.20 0.21
Non-Cash Adjustments To Reconcile Net Income		 0.38 0.69 0.61 0.86 0.72 0.70 0.42 0.63 0.87 0.68 0.86
Changes in Operating Assets and Liabilities, net		 7.95 0.66 0.17 -0.44 1.57 0.01 -0.88 0.01 0.53 -0.06 -1.11
Net Cash From Investing Activities		 -0.21 -0.13 -0.15 -1.10 0.05 -0.45 -0.03 -0.05 -0.42 -0.09 -0.58
Net Cash From Continuing Investing Activities		 -0.21 -0.13 -0.15 -1.10 0.05 -0.45 -0.03 -0.05 -0.42 -0.09 -0.58
Purchase of Property, Plant & Equipment		 -0.20 -0.13 -0.12 -1.08 0.04 -0.44 -0.03 -0.05 -0.41 -0.05 -0.16
Acquisitions		 -0.01 0.00 -0.02 -0.02 -0.00 -0.00 - - -0.02 -0.04 -0.42
Net Cash From Financing Activities		 -0.18 -0.18 -0.23 0.37 -0.22 -0.16 -0.19 0.40 -0.26 -0.03 -0.12
Net Cash From Continuing Financing Activities		 -0.18 -0.18 -0.23 0.37 -0.22 -0.16 -0.19 0.40 -0.26 -0.03 -0.12
Other Financing Activities, net		 -0.71 -0.03 -0.07 -0.43 0.31 -0.03 -0.05 -0.28 -0.26 -0.03 -0.12
Cash Interest Paid		 0.02 0.01 0.01 0.03 0.03 0.01 0.00 0.03 0.02 0.00 0.00

Annual Balance Sheets for KORU Medical Systems

This table presents KORU Medical Systems' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 2/29/2016 12/31/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 8.39 9.28 14 40 41 42 28 27 28
Total Current Assets		 7.12 7.93 12 38 37 30 20 19 20
Cash & Equivalents		 4.20 3.97 5.87 27 25 17 11 9.58 8.87
Accounts Receivable		 1.35 1.86 3.23 2.57 4.31 4.53 4.07 6.00 6.53
Inventories, net		 1.04 1.66 2.39 6.83 6.11 6.40 3.48 2.80 3.68
Prepaid Expenses		 0.27 0.17 0.39 0.81 1.57 1.46 1.22 0.75 0.91
Plant, Property, & Equipment, net		 1.00 0.84 0.61 1.17 1.11 3.89 3.84 4.29 4.47
Total Noncurrent Assets		 0.28 0.52 1.39 1.23 2.87 8.64 4.37 3.80 3.74
Intangible Assets		 0.25 0.48 0.81 0.84 0.81 0.79 0.75 0.73 0.68
Other Noncurrent Operating Assets		 0.03 0.03 0.39 0.26 0.12 3.89 3.61 3.07 3.06
Total Liabilities & Shareholders' Equity		 8.39 9.28 14 40 41 42 28 27 28
Total Liabilities		 1.28 1.61 2.65 3.76 4.79 11 8.11 10 11
Total Current Liabilities		 1.11 1.59 2.41 3.67 4.79 6.96 4.45 7.20 8.19
Accounts Payable		 0.31 0.45 0.57 0.62 1.23 2.39 0.98 1.65 2.27
Accrued Expenses		 0.50 0.66 1.30 2.61 2.71 2.89 1.71 3.92 4.83
Current Employee Benefit Liabilities		 0.15 0.33 0.19 0.29 0.16 0.54 0.46 0.81 0.53
Other Current Liabilities		 0.02 0.02 0.14 0.14 0.19 0.70 0.99 0.55 0.57
Total Noncurrent Liabilities		 0.17 0.03 0.24 0.10 0.00 4.05 3.65 3.20 2.96
Capital Lease Obligations		 0.04 0.00 - - 0.00 0.39 0.32 0.20 0.08
Other Noncurrent Operating Liabilities		 - - 0.24 0.10 0.00 3.65 3.34 3.00 2.88
Total Equity & Noncontrolling Interests		 7.12 7.67 11 36 37 31 20 17 17
Total Preferred & Common Equity		 7.12 7.67 11 36 37 31 20 17 17
Total Common Equity		 7.12 7.67 11 36 37 31 20 17 17
Common Stock		 4.37 4.62 6.72 36 41 45 48 50 53
Retained Earnings		 3.02 3.39 4.86 3.65 -0.91 -9.57 -23 -29 -32
Treasury Stock		 -0.25 -0.34 -0.34 -3.84 -3.84 -3.84 -3.84 -3.88 -3.88

Quarterly Balance Sheets for KORU Medical Systems

This table presents KORU Medical Systems' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 35 28 27 27 27 26 27 29 28
Total Current Assets		 22 19 19 19 19 18 19 21 20
Cash & Equivalents		 11 11 10 8.81 8.74 8.05 8.46 8.77 8.29
Accounts Receivable		 4.86 4.68 5.85 5.24 6.27 5.09 5.52 6.32 6.09
Inventories, net		 4.68 3.15 2.59 3.93 3.28 3.95 4.41 4.48 4.51
Prepaid Expenses		 1.37 0.83 0.47 0.96 0.71 0.49 1.03 1.03 0.62
Plant, Property, & Equipment, net		 3.82 3.76 3.68 4.55 4.53 4.37 4.24 4.34 3.93
Total Noncurrent Assets		 9.85 4.27 4.26 3.91 3.68 3.57 3.45 3.67 4.52
Intangible Assets		 0.76 0.74 0.75 0.75 0.72 0.70 0.68 0.71 1.66
Other Noncurrent Operating Assets		 3.64 3.53 3.51 3.16 2.97 2.87 2.77 2.96 2.85
Total Liabilities & Shareholders' Equity		 35 28 27 27 27 26 27 29 28
Total Liabilities		 7.92 8.38 8.60 9.66 11 8.99 11 12 9.91
Total Current Liabilities		 4.22 4.85 5.14 6.32 7.80 6.05 7.83 8.85 7.18
Accounts Payable		 0.95 1.77 1.60 1.67 2.01 1.09 1.87 2.64 2.91
Accrued Expenses		 1.46 1.46 2.14 2.79 3.98 3.64 4.63 5.27 2.87
Current Employee Benefit Liabilities		 0.39 0.52 0.44 0.77 1.04 0.69 0.46 0.39 0.81
Other Current Liabilities		 0.96 0.94 0.95 0.69 0.63 0.63 0.54 0.56 0.59
Total Noncurrent Liabilities		 3.70 3.53 3.46 3.33 3.07 2.94 2.80 2.82 2.73
Capital Lease Obligations		 0.32 0.29 0.26 0.23 0.17 0.15 0.12 0.05 0.07
Other Noncurrent Operating Liabilities		 3.38 3.24 3.20 3.10 2.90 2.79 2.69 2.77 2.66
Total Equity & Noncontrolling Interests		 27 19 19 18 16 17 16 17 18
Total Preferred & Common Equity		 27 19 19 18 16 17 16 17 18
Total Common Equity		 27 19 19 18 16 17 16 17 18
Common Stock		 47 48 49 49 51 51 52 55 57
Retained Earnings		 -16 -25 -26 -28 -31 -31 -32 -33 -33
Treasury Stock		 -3.84 -3.84 -3.88 -3.88 -3.88 -3.88 -3.88 -5.55 -6.41

Annual Metrics And Ratios for KORU Medical Systems

This table displays calculated financial ratios and metrics derived from KORU Medical Systems' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 2/28/2015 2/29/2016 2/28/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 38,081,667.00 38,006,667.00 37,749,081.00 38,216,932.00 39,501,870.00 43,942,888.00 44,561,160.00 45,279,948.00 45,669,362.00 - 46,322,655.00
DEI Adjusted Shares Outstanding		 38,081,667.00 38,006,667.00 37,749,081.00 38,216,932.00 39,501,870.00 43,942,888.00 44,561,160.00 45,279,948.00 45,669,362.00 - 46,322,655.00
DEI Earnings Per Adjusted Shares Outstanding		 0.02 0.02 -0.01 - 0.01 -0.03 -0.10 -0.19 -0.30 - -0.06
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 29.27% 0.00% 0.38% 41.16% 0.00% 4.38% -2.84% 18.76% 2.23% 17.98% 22.23%
EBITDA Growth		 15.97% 5.16% -130.87% 433.08% -30.25% -170.78% -797.07% -53.26% 11.74% 41.87% 62.65%
EBIT Growth		 6.70% 6.60% -167.61% 251.90% -40.83% -271.49% -489.93% -51.52% 8.45% 37.96% 55.30%
NOPAT Growth		 14.64% 0.66% -163.67% 277.66% -47.32% -368.32% -286.39% -53.37% 4.74% 37.23% 53.89%
Net Income Growth		 7.06% 0.00% -168.34% 270.20% 0.00% -314.77% -276.45% -89.82% -58.65% 55.85% 56.52%
EPS Growth		 0.00% 0.00% -150.00% 300.00% 0.00% -400.00% -233.33% -90.00% -57.89% 56.67% 53.85%
Operating Cash Flow Growth		 -13.44% 131.79% -117.32% 546.20% 0.00% -331.84% -481.11% -25.12% 9.47% 93.47% 244.63%
Free Cash Flow Firm Growth		 77.31% 228.48% -212.58% 116.04% -287.56% -300.35% -63.24% -36.93% 81.67% -39.57% 3.23%
Invested Capital Growth		 -8.91% 0.00% 0.00% 7.81% 44.84% 64.80% 32.04% 26.30% -35.56% -18.90% 7.11%
Revenue Q/Q Growth		 7.79% -1.75% -15.49% 17.73% 0.00% 0.00% 11.56% 3.16% -0.55% 5.17% 5.26%
EBITDA Q/Q Growth		 2.06% 61.92% -124.21% 134.13% 0.00% -290.37% -17.69% -2.27% 4.63% 7.93% 25.33%
EBIT Q/Q Growth		 -8.49% 93.19% -142.58% 261.73% 0.00% 0.00% -16.19% -2.87% 3.86% 7.09% 20.37%
NOPAT Q/Q Growth		 -4.93% 75.21% -143.83% 79.93% 0.00% 0.00% -15.60% -3.84% 2.97% 8.62% 25.96%
Net Income Q/Q Growth		 -9.39% 87.86% -144.34% 116.49% 0.00% 0.00% -5.40% -11.72% -66.52% 49.32% 28.94%
EPS Q/Q Growth		 -33.33% 0.00% -150.00% 100.00% 0.00% 0.00% 0.00% -5.56% -87.50% 50.00% 64.71%
Operating Cash Flow Q/Q Growth		 -44.04% 0.00% 73.00% 10.78% 0.00% -141.50% 18.72% 27.53% -5.15% -96.72% 50.49%
Free Cash Flow Firm Q/Q Growth		 117.71% -4.74% -75.89% -82.25% 79.82% -191.81% 2.92% 18.27% 75.33% -192.27% -54.36%
Invested Capital Q/Q Growth		 -16.20% 0.00% 0.40% 0.00% -8.75% 17.77% 3.89% -13.06% -45.52% -19.38% -2.34%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 59.47% 62.08% 61.57% 62.29% 64.13% 61.78% 58.62% 55.09% 58.59% 63.40% 62.26%
EBITDA Margin		 12.79% 11.80% -3.63% 8.56% 4.48% -3.04% -28.02% -36.16% -31.22% -15.38% -5.10%
Operating Margin		 10.20% 9.65% -5.99% 6.71% 2.53% -5.19% -29.93% -38.65% -36.01% -19.16% -7.23%
EBIT Margin		 9.56% 9.36% -6.30% 6.78% 3.01% -4.94% -29.99% -38.27% -34.27% -18.02% -7.07%
Profit (Net Income) Margin		 6.70% 6.39% -4.35% 5.25% 2.44% -5.01% -19.42% -31.05% -48.18% -18.03% -6.41%
Tax Burden Percent		 70.09% 68.52% 68.88% 77.37% 81.04% -101.49% 71.69% 81.13% 140.59% 100.05% 100.84%
Interest Burden Percent		 99.95% 99.70% 100.24% 100.00% 100.00% -100.00% 90.34% 100.00% 100.00% 100.00% 89.92%
Effective Tax Rate		 29.91% 31.48% 0.00% 22.63% 18.96% -1.49% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 28.39% 0.00% -30.00% 25.24% 10.47% -17.93% -47.97% -57.13% -59.30% -52.44% -26.07%
ROIC Less NNEP Spread (ROIC-NNEP)		 29.93% 0.00% -29.07% 25.04% 8.85% -18.30% -49.34% -51.74% -11.53% -36.87% -19.85%
Return on Net Nonoperating Assets (RNNOA)		 -16.16% 0.00% 16.05% -14.29% -8.77% 12.81% 35.41% 31.59% 6.12% 19.80% 10.49%
Return on Equity (ROE)		 12.24% 0.00% -13.95% 10.95% 1.70% -5.11% -12.56% -25.54% -53.18% -32.64% -15.58%
Cash Return on Invested Capital (CROIC)		 37.72% 0.00% -230.00% 17.72% -26.16% -66.87% -75.59% -80.37% -16.05% -31.57% -32.94%
Operating Return on Assets (OROA)		 14.72% 0.00% -8.35% 11.87% 10.03% -4.44% -17.35% -25.53% -27.61% -21.78% -10.50%
Return on Assets (ROA)		 10.31% 0.00% -5.76% 9.19% 8.13% -4.51% -11.24% -20.71% -38.82% -21.79% -9.52%
Return on Common Equity (ROCE)		 12.24% 0.00% -13.95% 10.95% 1.70% -5.11% -12.56% -25.54% -53.18% -32.64% -15.58%
Return on Equity Simple (ROE_SIMPLE)		 10.58% 0.00% -6.98% 10.16% 5.02% -3.35% -12.50% -27.65% -67.51% -36.08% 0.00%
Net Operating Profit after Tax (NOPAT)		 0.80 0.81 -0.52 0.90 0.47 -1.27 -4.92 -7.55 -7.19 -4.51 -2.08
NOPAT Margin		 7.15% 6.61% -4.19% 5.19% 2.05% -5.27% -20.95% -27.05% -25.21% -13.41% -5.06%
Net Nonoperating Expense Percent (NNEP)		 -1.54% 0.00% -0.93% 0.20% 1.61% 0.37% 1.37% -5.38% -47.77% -15.58% -6.23%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -34.26% -26.10% -12.15%
Cost of Revenue to Revenue		 40.53% 37.92% 38.43% 37.71% 35.87% 38.22% 41.38% 44.91% 41.41% 36.60% 37.74%
SG&A Expenses to Revenue		 42.58% 48.52% 63.18% 52.41% 42.19% 49.75% 76.04% 73.87% 71.41% 64.29% 56.84%
R&D to Revenue		 4.16% 1.69% 1.93% 1.39% 3.20% 5.36% 10.53% 17.77% 20.14% 15.63% 10.67%
Operating Expenses to Revenue		 49.27% 52.43% 67.56% 55.58% 61.60% 66.97% 88.54% 93.74% 94.60% 82.56% 69.48%
Earnings before Interest and Taxes (EBIT)		 1.08 1.15 -0.77 1.18 0.70 -1.19 -7.05 -11 -9.77 -6.06 -2.91
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 1.44 1.45 -0.45 1.49 1.04 -0.73 -6.58 -10 -8.90 -5.18 -2.10
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.75 0.00 1.61 0.00 22.96 7.32 3.66 5.16 5.51 10.50 15.79
Price to Tangible Book Value (P/TBV)		 1.82 0.00 1.72 0.00 24.73 7.49 3.75 5.29 5.72 10.97 16.45
Price to Revenue (P/Rev)		 1.11 1.02 1.01 0.00 11.14 10.94 5.69 5.79 3.93 5.24 6.54
Price to Earnings (P/E)		 16.59 15.92 0.00 0.00 457.07 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 6.03% 6.28% 0.00% 0.00% 0.22% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2.99 0.00 2.37 0.00 46.98 26.83 9.32 9.84 10.66 21.72 31.54
Enterprise Value to Revenue (EV/Rev)		 0.72 0.00 0.66 0.00 10.88 9.81 4.63 5.20 3.55 4.97 6.33
Enterprise Value to EBITDA (EV/EBITDA)		 5.61 0.00 0.00 0.00 243.17 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 7.51 0.00 0.00 0.00 361.96 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 10.04 0.00 0.00 0.00 531.12 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 9.77 0.00 0.00 0.00 786.22 0.00 0.00 0.00 0.00 0.00 563.02
Enterprise Value to Free Cash Flow (EV/FCFF)		 7.56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.03 0.03 0.03 0.00
Long-Term Debt to Equity		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.02 0.01 0.00
Financial Leverage		 -0.54 0.00 -0.55 -0.57 -0.99 -0.70 -0.72 -0.61 -0.53 -0.54 -0.53
Leverage Ratio		 1.19 0.00 1.21 1.19 1.24 1.14 1.12 1.23 1.37 1.50 1.64
Compound Leverage Factor		 1.19 0.00 1.21 1.19 1.24 -1.14 1.01 1.23 1.37 1.50 1.47
Debt to Total Capital		 0.63% 0.00% 0.05% 0.00% 0.00% 0.00% 1.37% 2.57% 3.01% 2.74% 0.46%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.37% 1.35% 1.50% 1.57% 0.00%
Long-Term Debt to Total Capital		 0.63% 0.00% 0.05% 0.00% 0.00% 0.00% 0.00% 1.23% 1.51% 1.17% 0.46%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.37% 0.00% 99.95% 100.00% 100.00% 100.00% 98.63% 97.43% 96.99% 97.26% 99.54%
Debt to EBITDA		 0.03 0.00 -0.01 0.00 0.00 0.00 -0.08 -0.08 -0.07 -0.09 -0.04
Net Debt to EBITDA		 -3.07 0.00 9.49 0.00 0.00 0.00 3.77 1.64 1.22 1.76 4.19
Long-Term Debt to EBITDA		 0.03 0.00 -0.01 0.00 0.00 0.00 0.00 -0.04 -0.04 -0.04 -0.04
Debt to NOPAT		 0.06 0.00 -0.01 0.00 0.00 0.00 -0.10 -0.11 -0.09 -0.11 -0.04
Net Debt to NOPAT		 -5.49 0.00 8.22 0.00 0.00 0.00 5.05 2.20 1.51 2.02 4.23
Long-Term Debt to NOPAT		 0.06 0.00 -0.01 0.00 0.00 0.00 0.00 -0.05 -0.04 -0.04 -0.04
Altman Z-Score		 9.00 0.00 6.99 0.00 61.64 43.84 17.66 8.97 7.69 9.69 14.51
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.43 0.00 5.00 5.70 4.94 10.24 7.79 4.28 4.55 2.66 2.44
Quick Ratio		 5.25 0.00 3.85 4.22 3.78 8.15 6.19 3.15 3.49 2.16 1.88
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 1.07 3.51 -3.95 0.63 -1.19 -4.75 -7.75 -11 -1.95 -2.72 -2.63
Operating Cash Flow to CapEx		 139.68% 1,769.17% -163.26% 508.44% 0.00% -83.00% -1,281.32% -195.74% -624.89% -24.81% 49.95%
Free Cash Flow to Firm to Interest Expense		 2,086.80 1,028.62 -2,094.94 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 1,613.47 561.20 -175.83 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 458.37 529.48 -283.53 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.54 0.00 1.32 1.75 3.34 0.90 0.58 0.67 0.81 1.21 1.48
Accounts Receivable Turnover		 7.27 0.00 6.60 10.56 0.00 8.33 6.82 6.31 6.63 6.68 6.57
Inventory Turnover		 4.90 0.00 2.85 3.48 0.00 2.00 1.50 2.00 2.39 3.92 4.79
Fixed Asset Turnover		 12.25 0.00 14.70 20.48 0.00 27.17 20.66 11.17 7.38 8.28 9.39
Accounts Payable Turnover		 16.44 0.00 10.40 14.41 0.00 15.43 10.49 6.92 7.01 9.38 7.93
Days Sales Outstanding (DSO)		 50.23 0.00 55.28 34.58 0.00 43.84 53.48 57.85 55.07 54.63 55.59
Days Inventory Outstanding (DIO)		 74.45 0.00 128.16 104.94 0.00 182.06 242.87 182.27 152.78 93.14 76.20
Days Payable Outstanding (DPO)		 22.20 0.00 35.11 25.32 0.00 23.65 34.78 52.73 52.03 38.90 46.06
Cash Conversion Cycle (CCC)		 102.48 0.00 148.33 114.20 0.00 202.25 261.57 187.39 155.82 108.87 85.74
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 2.70 0.00 3.44 3.70 5.37 8.84 12 15 9.50 7.71 8.25
Invested Capital Turnover		 3.97 0.00 7.16 4.86 5.11 3.40 2.29 2.11 2.35 3.91 5.15
Increase / (Decrease) in Invested Capital		 -0.26 -2.70 3.44 0.27 1.66 3.48 2.83 3.07 -5.24 -1.80 0.55
Enterprise Value (EV)		 8.07 0.00 8.15 0.00 252 237 109 145 101 167 260
Market Capitalization		 12 12 12 0.00 258 265 134 162 112 176 269
Book Value per Share		 $0.19 $0.00 $0.20 $0.23 $0.28 $0.82 $0.82 $0.69 $0.45 $0.37 $0.37
Tangible Book Value per Share		 $0.18 $0.00 $0.19 $0.21 $0.26 $0.80 $0.80 $0.67 $0.43 $0.35 $0.35
Total Capital		 7.16 0.00 7.67 8.96 11 36 37 32 21 17 17
Total Debt		 0.04 0.00 0.00 0.00 0.00 0.00 0.51 0.83 0.63 0.47 0.08
Total Long-Term Debt		 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.39 0.32 0.20 0.08
Net Debt		 -4.42 0.00 -4.23 -5.26 -5.87 -27 -25 -17 -11 -9.11 -8.79
Capital Expenditures (CapEx)		 0.59 0.11 0.20 0.29 -0.02 0.90 0.34 2.76 0.78 1.29 0.93
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 1.55 0.00 2.11 2.19 3.60 6.54 7.70 5.87 4.63 2.62 2.92
Debt-free Net Working Capital (DFNWC)		 6.01 0.00 6.34 7.45 9.48 34 33 23 16 12 12
Net Working Capital (NWC)		 6.01 0.00 6.34 7.45 9.48 34 33 23 16 12 12
Net Nonoperating Expense (NNE)		 0.05 0.03 0.02 -0.01 -0.09 -0.06 -0.36 1.11 6.55 1.55 0.56
Net Nonoperating Obligations (NNO)		 -4.42 0.00 -4.23 -5.26 -5.87 -27 -25 -17 -11 -9.11 -8.79
Total Depreciation and Amortization (D&A)		 0.36 0.30 0.33 0.31 0.34 0.46 0.46 0.59 0.87 0.89 0.81
Debt-free, Cash-free Net Working Capital to Revenue		 13.76% 0.00% 17.13% 12.63% 15.56% 27.07% 32.79% 21.03% 16.25% 7.79% 7.11%
Debt-free Net Working Capital to Revenue		 53.45% 0.00% 51.60% 42.92% 40.91% 140.05% 140.65% 83.44% 56.51% 36.26% 28.68%
Net Working Capital to Revenue		 53.45% 0.00% 51.60% 42.92% 40.91% 140.05% 138.48% 81.89% 55.41% 35.46% 28.68%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.02 ($0.01) $0.00 $0.00 ($0.03) ($0.10) ($0.19) ($0.30) ($0.13) ($0.06)
Adjusted Weighted Average Basic Shares Outstanding		 37.63M 37.99M 37.83M 0.00 0.00 41.93M 44.39M 45.00M 45.60M 45.80M 46.19M
Adjusted Diluted Earnings per Share		 $0.00 $0.02 ($0.01) $0.00 $0.00 ($0.03) ($0.10) ($0.19) ($0.30) ($0.13) ($0.06)
Adjusted Weighted Average Diluted Shares Outstanding		 37.63M 37.99M 37.88M 0.00 0.00 41.93M 44.39M 45.00M 45.60M 45.80M 46.19M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.02 ($0.01) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 38.01M 0.00 37.82M 0.00 0.00 44.48M 44.67M 45.52M 45.71M 45.96M 46.37M
Normalized Net Operating Profit after Tax (NOPAT)		 0.80 0.81 -0.52 0.90 3.24 0.83 -4.92 -7.55 -7.19 -4.51 -2.08
Normalized NOPAT Margin		 7.15% 6.61% -4.19% 5.19% 14.00% 3.45% -20.95% -27.05% -25.21% -13.41% -5.06%
Pre Tax Income Margin		 9.56% 9.33% -6.32% 6.78% 3.01% 4.94% -27.09% -38.27% -34.27% -18.02% -6.36%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 2,099.70 335.87 -410.82 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 1,570.66 237.24 -273.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 944.60 304.15 -518.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 415.56 205.52 -380.97 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 3.22% 10.29% -18.20% 0.00% 0.50% -288.71% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for KORU Medical Systems

This table displays calculated financial ratios and metrics derived from KORU Medical Systems' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 45,669,362.00 45,710,500.00 45,764,225.00 45,855,328.00 - 45,957,115.00 46,140,996.00 46,234,957.00 46,322,655.00 46,370,432.00 45,933,000.00
DEI Adjusted Shares Outstanding		 45,669,362.00 45,710,500.00 45,764,225.00 45,855,328.00 - 45,957,115.00 46,140,996.00 46,234,957.00 46,322,655.00 46,370,432.00 45,933,000.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.16 -0.04 -0.02 -0.03 - -0.03 0.00 -0.02 -0.01 -0.02 0.01
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -2.16% 10.89% 21.54% 16.80% 23.00% 17.53% 20.93% 27.17% 23.27% 22.10% 18.15%
EBITDA Growth		 19.44% 38.58% 73.26% -0.93% 24.87% 40.04% 102.59% 55.79% 68.91% 32.44% 792.51%
EBIT Growth		 16.24% 35.22% 68.06% -1.52% 22.89% 35.98% 80.83% 49.66% 62.91% 28.35% 173.89%
NOPAT Growth		 12.50% 35.84% 63.03% 4.90% 27.67% 36.52% 73.77% 49.06% 65.58% 30.53% 380.05%
Net Income Growth		 -277.70% 19.70% 60.39% -15.53% 79.09% 39.76% 79.08% 50.79% 68.81% 30.80% 222.03%
EPS Growth		 -466.67% 180.00% 140.00% 200.00% 76.47% -175.00% -100.00% -33.33% 50.00% 33.33% 0.00%
Operating Cash Flow Growth		 -17.93% 92.56% 107.36% 21.36% -14.33% 31.51% -4,161.23% 107.08% 16.51% 106.17% 146.95%
Free Cash Flow Firm Growth		 176.72% 202.84% 269.98% 485.72% -81.55% -100.59% -104.47% -92.52% -236.22% -1,759.62% -83.41%
Invested Capital Growth		 -35.56% -51.84% -49.14% -45.19% -18.90% -9.42% 1.31% -11.59% 7.11% 3.54% 14.14%
Revenue Q/Q Growth		 2.61% 14.08% 2.83% -2.97% 8.05% 9.01% 5.81% 2.03% 4.74% 7.98% 2.39%
EBITDA Q/Q Growth		 -23.41% 4.91% 54.78% -90.18% 0.46% 39.11% 102.11% -3,344.90% 19.50% -32.33% 159.14%
EBIT Q/Q Growth		 -21.12% 4.20% 48.93% -71.31% 1.43% 34.42% 83.75% -349.94% 17.79% -26.69% 122.34%
NOPAT Q/Q Growth		 -22.70% 10.75% 39.22% -42.89% 6.68% 21.67% 74.89% -177.52% 36.95% -58.09% 201.23%
Net Income Q/Q Growth		 -445.66% 74.07% 48.93% -59.89% 1.24% 25.30% 82.26% -276.07% 37.42% -65.77% 131.28%
EPS Q/Q Growth		 -466.67% 123.53% -50.00% 50.00% -33.33% 86.36% -100.00% 0.00% -650.00% 81.82% 150.00%
Operating Cash Flow Q/Q Growth		 193.36% -131.61% 103.27% -8,251.28% 201.70% -125.27% -93.85% 114.22% 1,572.51% -98.66% 1,373.87%
Free Cash Flow Firm Q/Q Growth		 313.60% 117.07% -8.17% -9.41% -89.79% -106.97% -592.58% 251.57% -286.13% 4.82% 31.69%
Invested Capital Q/Q Growth		 -45.52% -7.98% -2.73% 12.38% -19.38% 2.78% 8.79% -1.92% -2.34% -0.65% 19.93%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 60.27% 62.25% 65.00% 63.40% 62.94% 62.75% 63.52% 60.22% 62.57% 61.47% 65.14%
EBITDA Margin		 -24.95% -20.79% -9.14% -17.92% -15.24% -10.61% 0.20% -6.23% -4.79% -5.87% 3.39%
Operating Margin		 -30.58% -23.93% -14.14% -20.82% -17.98% -12.92% -3.07% -8.34% -5.02% -7.35% 5.21%
EBIT Margin		 -28.12% -23.62% -11.73% -20.71% -17.63% -12.86% -1.86% -8.20% -6.43% -7.55% 1.65%
Profit (Net Income) Margin		 -103.90% -23.62% -11.73% -19.33% -17.66% -12.10% -2.03% -7.48% -4.47% -6.86% 2.10%
Tax Burden Percent		 369.44% 100.00% 100.00% 100.00% 100.19% 100.00% 109.16% 99.98% 100.97% 100.00% 97.75%
Interest Burden Percent		 100.00% 100.00% 100.00% 93.33% 100.00% 94.10% 100.00% 91.26% 68.78% 90.88% 130.18%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.25%
Return on Invested Capital (ROIC)		 -50.35% -36.51% -24.18% -34.54% -49.23% -38.08% -9.24% -25.33% -18.11% -27.62% 24.88%
ROIC Less NNEP Spread (ROIC-NNEP)		 -7.14% -31.39% -22.75% -30.26% -44.73% -34.95% -9.37% -23.22% -16.95% -25.26% 29.35%
Return on Net Nonoperating Assets (RNNOA)		 3.79% 14.13% 10.49% 12.17% 24.02% 18.52% 4.82% 10.99% 8.96% 13.02% -13.69%
Return on Equity (ROE)		 -46.57% -22.38% -13.69% -22.37% -25.21% -19.56% -4.42% -14.34% -9.15% -14.60% 11.19%
Cash Return on Invested Capital (CROIC)		 -16.05% 22.24% 25.52% 21.81% -31.57% -38.25% -40.96% -18.91% -32.94% -25.99% -25.74%
Operating Return on Assets (OROA)		 -22.66% -21.06% -11.42% -21.12% -21.31% -16.50% -2.59% -11.75% -9.55% -11.70% 2.78%
Return on Assets (ROA)		 -83.71% -21.06% -11.42% -19.71% -21.35% -15.52% -2.83% -10.72% -6.63% -10.63% 3.54%
Return on Common Equity (ROCE)		 -46.57% -22.38% -13.69% -22.37% -25.21% -19.56% -4.42% -14.34% -9.15% -14.60% 11.19%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -69.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.54 -1.37 -0.83 -1.19 -1.11 -0.87 -0.22 -0.61 -0.38 -0.61 0.61
NOPAT Margin		 -21.41% -16.75% -9.90% -14.58% -12.59% -9.05% -2.15% -5.84% -3.52% -5.15% 5.09%
Net Nonoperating Expense Percent (NNEP)		 -43.22% -5.12% -1.43% -4.28% -4.49% -3.14% 0.13% -2.11% -1.16% -2.35% -4.47%
Return On Investment Capital (ROIC_SIMPLE)		 -7.33% -7.02% -4.40% -6.49% -6.44% -5.23% -1.31% -3.59% -2.24% -3.57% 3.38%
Cost of Revenue to Revenue		 39.73% 37.75% 35.00% 36.60% 37.06% 37.25% 36.48% 39.78% 37.43% 38.53% 34.86%
SG&A Expenses to Revenue		 69.76% 65.35% 63.10% 62.69% 65.92% 61.85% 52.81% 57.63% 55.44% 55.95% 49.31%
R&D to Revenue		 17.92% 18.00% 13.45% 18.75% 12.61% 11.57% 11.72% 8.97% 10.51% 11.19% 8.88%
Operating Expenses to Revenue		 90.85% 86.18% 79.14% 84.22% 80.92% 75.68% 66.59% 68.57% 67.59% 68.82% 59.93%
Earnings before Interest and Taxes (EBIT)		 -2.02 -1.94 -0.99 -1.69 -1.56 -1.24 -0.19 -0.85 -0.70 -0.89 0.20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.79 -1.70 -0.77 -1.47 -1.35 -1.02 0.02 -0.65 -0.52 -0.69 0.41
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.51 5.64 6.48 7.06 10.50 7.14 10.00 10.76 15.79 11.84 10.69
Price to Tangible Book Value (P/TBV)		 5.72 5.87 6.75 7.37 10.97 7.47 10.44 11.22 16.45 12.36 11.77
Price to Revenue (P/Rev)		 3.93 3.68 3.94 3.91 5.24 3.33 4.48 4.53 6.54 4.63 4.28
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 10.66 11.15 13.06 12.24 21.72 13.67 18.25 20.00 31.54 23.36 18.78
Enterprise Value to Revenue (EV/Rev)		 3.55 3.33 3.60 3.66 4.97 3.09 4.27 4.33 6.33 4.43 4.09
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 550.23 563.02 268.15 132.79
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 32.59 34.50 39.75 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.03 0.02 0.01 0.04 0.03 0.02 0.01 0.03 0.00 0.00 0.00
Long-Term Debt to Equity		 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00
Financial Leverage		 -0.53 -0.45 -0.46 -0.40 -0.54 -0.53 -0.51 -0.47 -0.53 -0.52 -0.47
Leverage Ratio		 1.37 1.34 1.35 1.39 1.50 1.54 1.50 1.59 1.64 1.68 1.55
Compound Leverage Factor		 1.37 1.34 1.35 1.30 1.50 1.45 1.50 1.45 1.13 1.52 2.01
Debt to Total Capital		 3.01% 2.29% 1.37% 3.44% 2.74% 1.87% 0.87% 2.67% 0.46% 0.27% 0.39%
Short-Term Debt to Total Capital		 1.50% 0.81% 0.00% 2.19% 1.57% 0.82% 0.00% 1.98% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 1.51% 1.47% 1.37% 1.25% 1.17% 1.05% 0.87% 0.69% 0.46% 0.27% 0.39%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 96.99% 97.71% 98.63% 96.56% 97.26% 98.13% 99.13% 97.33% 99.54% 99.73% 99.61%
Debt to EBITDA		 -0.07 -0.06 -0.05 -0.11 -0.09 -0.06 -0.04 -0.16 -0.04 -0.03 -0.05
Net Debt to EBITDA		 1.22 1.32 1.78 1.43 1.76 1.71 2.18 2.85 4.19 4.93 6.32
Long-Term Debt to EBITDA		 -0.04 -0.04 -0.05 -0.04 -0.04 -0.04 -0.04 -0.04 -0.04 -0.03 -0.05
Debt to NOPAT		 -0.09 -0.07 -0.05 -0.13 -0.11 -0.08 -0.04 -0.16 -0.04 -0.03 -0.06
Net Debt to NOPAT		 1.51 1.62 2.04 1.66 2.02 2.10 2.33 2.85 4.23 4.81 7.10
Long-Term Debt to NOPAT		 -0.04 -0.04 -0.05 -0.05 -0.04 -0.04 -0.04 -0.04 -0.04 -0.03 -0.06
Altman Z-Score		 8.58 7.91 8.75 7.87 10.24 6.50 11.30 10.21 14.77 10.60 12.21
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.55 4.01 3.77 2.99 2.66 2.44 2.91 2.48 2.44 2.33 2.72
Quick Ratio		 3.49 3.19 3.17 2.22 2.16 1.92 2.17 1.78 1.88 1.70 2.00
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 3.70 8.04 7.38 6.69 0.68 -0.05 -0.33 0.50 -0.93 -0.89 -0.61
Operating Cash Flow to CapEx		 559.45% -260.53% 9.12% -85.26% 0.00% -53.55% -1,597.63% 124.72% 268.47% 31.76% 135.03%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.81 0.89 0.97 1.02 1.21 1.28 1.40 1.43 1.48 1.55 1.69
Accounts Receivable Turnover		 6.63 5.95 5.81 6.33 6.68 6.41 6.74 7.27 6.57 6.87 8.07
Inventory Turnover		 2.39 2.38 2.94 2.76 3.92 3.99 4.15 3.53 4.79 4.25 4.01
Fixed Asset Turnover		 7.38 7.65 8.23 7.64 8.28 8.46 9.16 8.89 9.39 9.75 10.87
Accounts Payable Turnover		 7.01 7.11 7.29 9.09 9.38 6.76 10.09 8.31 7.93 7.08 8.46
Days Sales Outstanding (DSO)		 55.07 61.37 62.87 57.63 54.63 56.97 54.16 50.23 55.59 53.11 45.24
Days Inventory Outstanding (DIO)		 152.78 153.19 124.19 132.04 93.14 91.56 87.86 103.39 76.20 85.94 91.09
Days Payable Outstanding (DPO)		 52.03 51.30 50.05 40.14 38.90 53.97 36.16 43.92 46.06 51.52 43.15
Cash Conversion Cycle (CCC)		 155.82 163.25 137.02 149.53 108.87 94.56 105.86 109.71 85.74 87.53 93.18
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 9.50 8.74 8.51 9.56 7.71 7.92 8.62 8.45 8.25 8.20 9.84
Invested Capital Turnover		 2.35 2.18 2.44 2.37 3.91 4.21 4.30 4.34 5.15 5.37 4.89
Increase / (Decrease) in Invested Capital		 -5.24 -9.41 -8.22 -7.88 -1.80 -0.82 0.11 -1.11 0.55 0.28 1.22
Enterprise Value (EV)		 101 98 111 117 167 108 157 169 260 192 185
Market Capitalization		 112 108 121 125 176 117 165 177 269 200 193
Book Value per Share		 $0.45 $0.42 $0.41 $0.39 $0.37 $0.36 $0.36 $0.36 $0.37 $0.36 $0.39
Tangible Book Value per Share		 $0.43 $0.40 $0.39 $0.37 $0.35 $0.34 $0.34 $0.34 $0.35 $0.35 $0.36
Total Capital		 21 20 19 18 17 17 17 17 17 17 18
Total Debt		 0.63 0.45 0.26 0.63 0.47 0.31 0.15 0.45 0.08 0.05 0.07
Total Long-Term Debt		 0.32 0.29 0.26 0.23 0.20 0.17 0.15 0.12 0.08 0.05 0.07
Net Debt		 -11 -10 -10 -8.17 -9.11 -8.42 -7.91 -8.01 -8.79 -8.72 -8.22
Capital Expenditures (CapEx)		 0.20 0.13 0.12 1.08 -0.04 0.44 0.03 0.05 0.41 0.05 0.16
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 4.63 3.97 3.77 4.20 2.62 2.60 3.47 3.46 2.92 2.97 4.05
Debt-free Net Working Capital (DFNWC)		 16 15 14 13 12 11 12 12 12 12 12
Net Working Capital (NWC)		 16 15 14 13 12 11 12 12 12 12 12
Net Nonoperating Expense (NNE)		 5.93 0.56 0.15 0.39 0.45 0.29 -0.01 0.17 0.10 0.20 0.36
Net Nonoperating Obligations (NNO)		 -11 -10 -10 -8.17 -9.11 -8.42 -7.91 -8.01 -8.79 -8.72 -8.22
Total Depreciation and Amortization (D&A)		 0.23 0.23 0.22 0.23 0.21 0.22 0.21 0.20 0.18 0.20 0.21
Debt-free, Cash-free Net Working Capital to Revenue		 16.25% 13.52% 12.24% 13.13% 7.79% 7.41% 9.43% 8.85% 7.11% 6.86% 8.97%
Debt-free Net Working Capital to Revenue		 56.51% 50.42% 46.17% 40.65% 36.26% 32.31% 31.29% 30.51% 28.68% 27.13% 27.34%
Net Working Capital to Revenue		 55.41% 49.88% 46.17% 39.40% 35.46% 31.92% 31.29% 29.65% 28.68% 27.13% 27.34%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.17) ($0.04) ($0.02) ($0.03) ($0.04) $0.03 $0.00 $0.00 $0.00 ($0.02) $0.01
Adjusted Weighted Average Basic Shares Outstanding		 45.60M 45.71M 45.81M 45.85M 45.80M 45.98M 46.23M 46.32M 46.19M 46.36M 46.08M
Adjusted Diluted Earnings per Share		 ($0.17) ($0.04) ($0.02) ($0.03) ($0.04) $0.03 $0.00 $0.02 ($0.11) ($0.02) $0.01
Adjusted Weighted Average Diluted Shares Outstanding		 45.60M 45.71M 45.81M 45.85M 45.80M 45.98M 46.19M 46.24M 46.19M 46.36M 49.51M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 45.71M 45.76M 45.86M 45.84M 45.96M 46.14M 46.23M 46.32M 46.37M 45.93M 46.17M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.54 -1.37 -0.83 -1.19 -1.11 -0.87 -0.22 -0.61 -0.38 -0.61 0.61
Normalized NOPAT Margin		 -21.41% -16.75% -9.90% -14.58% -12.59% -9.05% -2.15% -5.84% -3.52% -5.15% 5.09%
Pre Tax Income Margin		 -28.12% -23.62% -11.73% -19.33% -17.63% -12.10% -1.86% -7.48% -4.43% -6.86% 2.14%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

KORU Medical Systems’ recent results show a meaningful improvement in operating performance, although the recovery remains uneven. Revenue increased from $7.0 million in Q3 2023 to $12.0 million in Q2 2026. On a year-over-year basis, Q2 2026 revenue rose approximately 18% from the restated Q2 2025 figure.

Profitability also improved in the latest quarter. Gross profit increased to $7.85 million, while the gross margin expanded to approximately 65.1% from 63.5% a year earlier. KORU generated $627,000 of operating income and $252,000 of net income in Q2 2026, compared with operating and net losses in Q2 2025. However, this follows losses in Q3 2025, Q4 2025, and Q1 2026, so investors should watch whether profitability can be sustained.

The balance sheet remains relatively liquid, with $8.3 million of cash and a current ratio of approximately 2.7 at June 30, 2026. Debt is modest, but cash has declined from $10.5 million in Q2 2024 and fell by approximately $480,000 during Q2 2026. The company’s retained earnings deficit also widened to approximately $32.6 million, reflecting its history of losses.

  • Revenue growth is accelerating: Quarterly revenue increased from $7.0 million in Q3 2023 to $12.0 million in Q2 2026, with Q2 2026 revenue up approximately 18% year over year.
  • Gross margins improved: Q2 2026 gross margin reached approximately 65.1%, supported by gross profit growth that outpaced revenue growth.
  • Return to operating profitability: KORU produced $627,000 of operating income in Q2 2026, a significant improvement from the $865,000 operating loss in Q1 2026 and the $313,000 loss in restated Q2 2025.
  • Net income turned positive: Q2 2026 net income was $252,000, compared with a $807,000 loss in Q1 2026 and a $207,000 loss in restated Q2 2025.
  • Debt exposure appears manageable: Total liabilities were $9.9 million at June 30, 2026, while cash stood at $8.3 million and capital lease obligations were only $71,000.
  • Operating cash flow has improved but remains volatile: Operating cash flow was positive in Q2 2026 at $216,000, following $14,000 in Q1 2026 and $1.1 million in Q4 2025, but it was negative in Q1 and Q2 2025.
  • Growth investments are continuing: KORU spent $417,000 on acquisitions and $160,000 on property and equipment in Q2 2026. These investments could support future growth, but their returns are not yet clear from the financial statements.
  • Cash balances are trending below prior-year levels: Cash declined to $8.3 million from $10.5 million in Q2 2024 and fell $480,000 during Q2 2026 because investing and financing outflows exceeded operating cash generation.
  • Profitability has not yet been consistent: The company reported operating losses in Q3 2025, Q4 2025, and Q1 2026 before returning to profit in Q2 2026.
  • Shareholder equity remains pressured: Retained earnings were negative $32.6 million in Q2 2026, and total equity of $18.1 million was below the $18.7 million reported in Q2 2024. Investors should also monitor potential dilution, as Q2 diluted weighted-average shares exceeded basic shares.
10/14/26 02:08 PM ETAI Generated. May Contain Errors.

KORU Medical Systems Financials - Frequently Asked Questions

According to the most recent income statement we have on file, KORU Medical Systems' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

KORU Medical Systems' net income appears to be on a downward trend, with a most recent value of -$2.64 million in 2025, compared with $782.86 thousand in 2015. The previous period was -$6.07 million in 2024. View KORU Medical Systems' forecast to see where analysts expect KORU Medical Systems to go next.

KORU Medical Systems' total operating income in 2025 was -$2.97 million, based on the following breakdown:
  • Total Gross Profit: $25.60 million
  • Total Operating Expenses: $28.58 million

Over the last 10 years, KORU Medical Systems' total revenue changed from $12.25 million in 2015 to $41.13 million in 2025, a change of 235.8%.

In the past 11 quarters, KORU Medical Systems' cash and equivalents has ranged from $8.05 million in Q2 2025 to $10.82 million in Q1 2024, and is currently $8.29 million as of their latest financial filing in Q2 2026.

KORU Medical Systems had total debt of $78.68 thousand at the end of 2025, a 83.4% decrease from 2024, and a 74.9% increase since 2015.

Over the last 10 years, KORU Medical Systems' book value per share changed from 0.19 in 2015 to 0.37 in 2025, a change of 96.9%.


Related Companies

Financial statements for NASDAQ:KRMD last updated on 8/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Elon says the ‘S’ word
Elon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men d...
Paradigm Press | Sponsoredtc pixel
A simple options strategy that changed one trader's path
Ian Cooper went from a financially stressed, struggling journalist to a trader who discovered a repeatable opt...
TradeWins | Sponsoredtc pixel
Wall Street legend reveals his top AI stock before Oct. 20
Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...
Chaikin Analytics | Sponsoredtc pixel
My next big call (under $1)
The obvious way to "bet on Trump" in crypto is the Trump memecoin. And right now it's back in the news, with a...
Crypto 101 Media | Sponsoredtc pixel
Trump's about to unleash his Midterm Weapon
Trump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...
Monument Traders Alliance | Sponsoredtc pixel
5 seconds
Bill Poulos put together a Top 10 Stocks to Buy This Quarter report, explaining each pick in plain English. ...
Profits Run | Sponsoredtc pixel
Why Some AI Stocks Already Surged Over 300 Percent
Jason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...
Brownstone Research | Sponsoredtc pixel
The Iran War Isn’t Chaos. It’s Strategy.
Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...
Behind the Markets | Sponsoredtc pixel